Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Raw Materials (2019 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Raw Materials for 7 consecutive years, with $5.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Raw Materials fell 21.9% to $5.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.6 million, a 21.9% decrease, with the full-year FY2024 number at $6.6 million, down 8.9% from a year prior.
  • Raw Materials was $5.6 million for Q3 2025 at Xtant Medical Holdings, up from $5.4 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $7.3 million in Q4 2023 to a low of $3.8 million in Q1 2021.
  • A 5-year average of $5.9 million and a median of $5.6 million in 2022 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: soared 49.4% in 2021, then dropped 23.22% in 2025.
  • Xtant Medical Holdings' Raw Materials stood at $5.6 million in 2021, then increased by 0.27% to $5.6 million in 2022, then grew by 29.16% to $7.3 million in 2023, then dropped by 8.9% to $6.6 million in 2024, then fell by 15.42% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Raw Materials are $5.6 million (Q3 2025), $5.4 million (Q2 2025), and $5.4 million (Q1 2025).